Rappta Therapeutics

Rappta Therapeutics is a biopharmaceutical company based in Helsinki, founded in 2019.

The company is dedicated to developing innovative anti-cancer drugs by reactivating the tumor suppressor protein phosphatase 2A (PP2A). Their approach involves proprietary small-molecule compounds that function as "molecular glues," facilitating the binding of PP2A's subunits to restore its complex formation and target oncogenic signaling pathways. Currently, Rappta's product pipeline is in the preclinical stage, featuring compounds that represent a new class of anti-cancer drugs. One notable compound, RPT04402, has been identified in a licensing deal for its potential as a first-in-class molecular glue targeting PP2A complexes. The company has operations in both Finland and the US and has engaged in collaborations, including a global license agreement with SpringWorks Therapeutics for RPT04402.